Question · Q2 2017
George Goodman of Jericho Partners inquired about Microbot's strategy for its intellectual property portfolio, specifically the potential for partnering with larger companies. He also asked about future financing needs, the expected timeline for FDA approval of the Self-Cleaning Shunt, and the current competitive landscape.
Answer
Harel Gadot, CEO, President and Chairman, explained that while the company is exploring partnerships, its unique core capabilities are a key asset that larger firms seek. He confirmed the recent financing provides a 24-30 month cash runway and that they will continue to explore non-dilutive grants. Regarding the FDA, Mr. Gadot detailed the 510(k) pathway, targeting a late 2018 submission, which could result in a 3-6 month review. He characterized the market as a "blue ocean," with no direct competitors for a self-cleaning shunt.